Novozymes OneHealth cultivates global probiotic market to help develop industry | investinchina.chinadaily.com.cn

Novozymes OneHealth cultivates global probiotic market to help develop industry

chinadaily.com.cn Updated: May 29, 2023
Jordan F Dow, head of Global Commercial at Novozymes OneHealth, receives an interview at the 2023 China Gut Conference in Beijing. [Photo provided to chinadaily.com.cn]

The CHINAGUT 2023 Conference Series was held at the China National Convention Center in Beijing from May 20 to 22.

Jordan F Dow, head of Global Commercial at Novozymes OneHealth, said during an interview with chinadaily.com.cn that there was a vast amount of breakthrough research on probiotics at the conference compared with that at foreign exhibitions.

The conference not only aims to display goods, but also highlight breakthrough research in the intestinal tract.

According to Jordan, the number of microorganisms in the human intestinal tract has reached about 100 trillion, consisting of 2,000 different bacterial strains or species. Identifying and selecting specific single strains of bacteria is a complicated task.

Since its establishment in 2016, OneHealth has been adhering to the product concept of "one in a trillion". It creates scientific and healthy solutions through methods based on "evidence-based science", such as scientific research expansion and talent exchange, to customize target products for consumer groups of different ages.

CONTACT US

Reach out to us for information on how we can facilitate your investment journey

* Please leave a message
* Your Email Address
SUBMIT
Copyright©2024 China Daily. All rights reserved.

Novozymes OneHealth cultivates global probiotic market to help develop industry

chinadaily.com.cn Updated: May 29, 2023
Jordan F Dow, head of Global Commercial at Novozymes OneHealth, receives an interview at the 2023 China Gut Conference in Beijing. [Photo provided to chinadaily.com.cn]

The CHINAGUT 2023 Conference Series was held at the China National Convention Center in Beijing from May 20 to 22.

Jordan F Dow, head of Global Commercial at Novozymes OneHealth, said during an interview with chinadaily.com.cn that there was a vast amount of breakthrough research on probiotics at the conference compared with that at foreign exhibitions.

The conference not only aims to display goods, but also highlight breakthrough research in the intestinal tract.

According to Jordan, the number of microorganisms in the human intestinal tract has reached about 100 trillion, consisting of 2,000 different bacterial strains or species. Identifying and selecting specific single strains of bacteria is a complicated task.

Since its establishment in 2016, OneHealth has been adhering to the product concept of "one in a trillion". It creates scientific and healthy solutions through methods based on "evidence-based science", such as scientific research expansion and talent exchange, to customize target products for consumer groups of different ages.

Invest in China Copyright © 2024 China Daily All rights Reserved
京ICP备13028878号-6

京公网安备 11010502032503号